Brokerages Set Atossa Genetics Inc. (NASDAQ:ATOS) Price Target at $20.33

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have received an average recommendation of “Hold” from the five brokerages that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $20.3333.

A number of research analysts have issued reports on the stock. Ascendiant Capital Markets cut their target price on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, April 10th. Weiss Ratings cut shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Finally, Rodman & Renshaw began coverage on shares of Atossa Genetics in a research note on Tuesday, July 7th. They set a “buy” rating and a $12.00 price target for the company.

Atossa Genetics Stock Up 4.8%

Shares of ATOS opened at $2.17 on Friday. Atossa Genetics has a 12-month low of $1.70 and a 12-month high of $19.35. The firm has a market capitalization of $18.68 million, a PE ratio of -0.68 and a beta of 1.29. The stock’s fifty day simple moving average is $2.84 and its 200-day simple moving average is $4.66.

Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings results on Friday, May 8th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.12). Analysts anticipate that Atossa Genetics will post -4.3 EPS for the current year.

Institutional Trading of Atossa Genetics

Institutional investors have recently bought and sold shares of the business. &PARTNERS bought a new stake in shares of Atossa Genetics during the 4th quarter valued at $25,000. Hudson Bay Capital Management LP bought a new position in shares of Atossa Genetics in the 2nd quarter worth $26,000. JPMorgan Chase & Co. boosted its position in shares of Atossa Genetics by 1,294.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after purchasing an additional 35,474 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Atossa Genetics by 55.7% during the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock worth $83,000 after purchasing an additional 35,629 shares during the period. Finally, XTX Topco Ltd grew its stake in shares of Atossa Genetics by 581.2% during the fourth quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock worth $100,000 after purchasing an additional 144,412 shares during the period. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.